Systrade AG Makes New $11.45 Million Investment in Natera, Inc. $NTRA

Systrade AG acquired a new stake in shares of Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 50,000 shares of the medical research company’s stock, valued at approximately $11,454,000. Natera comprises 7.0% of Systrade AG’s holdings, making the stock its 5th largest position.

A number of other institutional investors have also added to or reduced their stakes in the company. Horizon Investments LLC bought a new stake in shares of Natera in the 3rd quarter worth approximately $32,000. Sound Income Strategies LLC increased its position in shares of Natera by 95.7% during the third quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 110 shares during the period. Quent Capital LLC acquired a new position in shares of Natera in the third quarter valued at $46,000. Hilltop National Bank raised its stake in shares of Natera by 59.8% in the third quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock valued at $50,000 after purchasing an additional 116 shares in the last quarter. Finally, N.E.W. Advisory Services LLC lifted its position in Natera by 256.8% in the second quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock worth $53,000 after purchasing an additional 226 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Up 2.5%

Shares of Natera stock opened at $200.09 on Tuesday. The stock has a market capitalization of $28.36 billion, a P/E ratio of -130.78 and a beta of 1.65. The company has a 50-day simple moving average of $214.57 and a 200 day simple moving average of $208.02. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.81. The firm had revenue of $665.50 million during the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same period last year, the firm posted ($0.41) EPS. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Barclays boosted their price target on shares of Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Morgan Stanley reduced their price objective on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. TD Cowen reiterated a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. JPMorgan Chase & Co. increased their price target on shares of Natera from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Finally, Canaccord Genuity Group restated a “buy” rating on shares of Natera in a research note on Monday, January 12th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.47.

Insider Activity

In other news, CEO Steven Leonard Chapman sold 85,299 shares of Natera stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $230.72, for a total value of $19,680,185.28. Following the completion of the transaction, the chief executive officer owned 127,881 shares in the company, valued at approximately $29,504,704.32. The trade was a 40.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Solomon Moshkevich sold 23,205 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total value of $5,447,141.70. Following the sale, the insider owned 144,992 shares in the company, valued at approximately $34,035,422.08. This trade represents a 13.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 318,344 shares of company stock worth $74,091,416. 5.63% of the stock is currently owned by insiders.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.